This innovative drug combination treatment focuses on boosting safety and efficacy in mental health and addiction care TEL AVIV, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. ("Clearmind") (Nasdaq: CMND) (FSE: CWY ...

To date, SciSparc has advanced $4.25 million to Automax under the Bridge Loan agreement and amendments thereto TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that it had entered into a second amendment (the "Second Amendment") to that certain bridge loan agreement, dated January 1 ...

Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments TEL AVIV, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. ("Clearmind") (Nasdaq: CMND) (CSE: CMND) (FSE: ...

TEL AVIV, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. ("Clearmind") (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to ...

SciSparc would be entitled to receive consideration valued at $3 million in Polyrizon securities, as well as potential milestone fees of approximately $3 million in cash TEL AVIV, Israel, Aug. 28, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that it has finalized an Exclusive Patent License Agreement ("the ...

SciSparc to conduct the trial at the Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel TEL AVIV, Israel, Aug. 23, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced the submission of an Investigational New Dr ...

Company Overview - SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and cannabinoid pharmaceuticals [5] - The company is engaged in drug development programs targeting conditions such as Tourette Syndrome, Alzheimer's disease, pain, and autism spectrum disorder (ASD) [5] Recent Developments - MitoCareX Bio Ltd., a venture of SciSparc, has appointed Professor Nir Peled to its scientific advisory board, enhancing its expertise in cancer therapeutics [1][4] - MitoCareX is focused on drug discovery targeting the mitochondrial SLC25 protein family, with recent validation of its target using Non-Small Cell Lung Cancer (NSCLC) cells [4] Research and Contributions - Professor Peled is a recognized expert in thoracic oncology with over 250 peer-reviewed publications, contributing significantly to lung cancer research and treatment [2][3] - His work includes personalized targeted therapy, immunotherapy, biomarker development, and early detection of lung cancer [3] Technological Advancements - MitoCareX has utilized advanced computational drug discovery platforms, including the proprietary MITOLINE™ algorithm, to screen millions of small molecules for potential anti-cancer treatments [4]

Core Viewpoint - SciSparc Ltd. is advancing its clinical trial for SCI-210, a treatment for autism spectrum disorder (ASD), with the first five patients enrolled in Israel, aiming for commercialization in the Israeli market first [1][3]. Group 1: Clinical Trial Details - The ongoing clinical trial is a double-blind, randomized, and placebo-controlled study involving 60 subjects aged 5 to 18 over a 20-week period [2]. - The trial will assess the efficacy of SCI-210, which combines cannabidiol (CBD) and CannAmide™, against standard CBD monotherapy in managing ASD symptoms [2][3]. - Primary efficacy metrics include the Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire, Clinical Global Impressions-Improvement (CGI-I) by clinicians, and effective therapeutic dose [3]. Group 2: Company Overview - SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on cannabinoid pharmaceuticals, with other drug development programs targeting Tourette Syndrome, Alzheimer's disease, and pain management [6]. - The company is led by an experienced team and aims to enhance its portfolio of technologies and assets based on cannabinoids [6]. Group 3: ASD Context - Autism spectrum disorder (ASD) affects social interaction and communication, with a wide range of symptoms and severity [5]. - Treatments and services can improve symptoms and daily functioning for individuals diagnosed with ASD [4].

SciSparc will receive consideration in shares, and in addition may receive cash payments and fees if certain development milestones are met TEL AVIV, Israel, Aug. 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that it has signed an Exclusive Patent License Agreement (the "License Agreement") with Polyriz ...

SciSparc provides investors with an update regarding the status of the merger agreement with AutoMax, including the court's approval of AutoMax's petition to convene special class meetings of its shareholders to approve the Merger with the Company TEL AVIV, Israel, Aug. 14, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous syste ...